Cargando…

Lifestyle or pharmacotherapy in cardio-metabolic disease prevention

Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seidu, Borenyi S., Osman, Hanad, Seidu, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334018/ https://www.ncbi.nlm.nih.gov/pubmed/37381922 http://dx.doi.org/10.1177/17539447231177175

Ejemplares similares

Prediabetes: lifestyle, pharmacotherapy or regulation?
por: Shaw, Jonathan E.
Publicado: (2019)

Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy
por: Jacob, Eden Mariam, et al.
Publicado: (2020)

Lifestyle Modification in the Management of Metabolic Syndrome: Statement From Korean Society of CardioMetabolic Syndrome (KSCMS)
por: Kim, Hack-Lyoung, et al.
Publicado: (2021)

Exploring the Interrelationships between Diabetes, Nutrition, Anxiety, and Depression: Implications for Treatment and Prevention Strategies
por: Basiri, Raedeh, et al.
Publicado: (2023)

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
por: Albini, Adriana, et al.
Publicado: (2010)

The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
por: Lee, Minyi, et al.
Publicado: (2019)

CARDIOPROTECTIVE MECHANISMS OF LIFESTYLE MODIFICATIONS AND PHARMACOTHERAPIES ON CARDIAC REMODELING AND DYSFUNCTION IN HYPERTENSIVE HEART DISEASE: AN OVERVIEW
por: NAGATA, KOHZO, et al.
Publicado: (2011)

INDY as a Therapeutic Target for Cardio-Metabolic Disease
por: Pesta, Dominik, et al.
Publicado: (2022)

Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
por: Khunti, Sachin, et al.
Publicado: (2019)

Linking Mediterranean Diet and Lifestyle with Cardio Metabolic Disease and Depressive Symptoms: A Study on the Elderly in Europe
por: Vall Castelló, Judit, et al.
Publicado: (2020)

Sleep and Cardio-Metabolic Disease
por: Cappuccio, Francesco P., et al.
Publicado: (2017)

11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases
por: Kupczyk, Daria, et al.
Publicado: (2022)

Preventive pharmacotherapy in type 2 diabetes mellitus
por: Choudhary, Neeraj, et al.
Publicado: (2012)

Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines
por: MacDonald, Blair J., et al.
Publicado: (2023)

The gut microbiome in cardio-metabolic health
por: Hansen, Tue H, et al.
Publicado: (2015)

Nuts and Cardio-Metabolic Disease: A Review of Meta-Analyses
por: Kim, Yoona, et al.
Publicado: (2018)

Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease
por: El Hadi, Hamza, et al.
Publicado: (2019)

The Effects of Shift Work on Cardio-Metabolic Diseases and Eating Patterns
por: Hemmer, Alexandra, et al.
Publicado: (2021)

Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases
por: Strassheim, Derek, et al.
Publicado: (2021)

Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
por: Tamargo, Juan, et al.
Publicado: (2022)

Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases
por: Rosolova, Hana, et al.
Publicado: (2011)

Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
por: Shao, Yaodi, et al.
Publicado: (2023)

Elucidating the novel biomarker and therapeutic potentials of High-mobility group box 1 in Subarachnoid hemorrhage: A review
por: Richard, Seidu A.
Publicado: (2019)

EPAC2: A new and promising protein for glioma pathogenesis and therapy
por: Richard, Seidu A.
Publicado: (2020)

Pathophysiology, pharmacotherapy, cardiovascular disease
por: Sharma, Kamal H.
Publicado: (2015)

Novel Pharmacotherapies in Parkinson’s Disease
por: Tizabi, Yousef, et al.
Publicado: (2021)

Ketogenic Diets and Cardio-Metabolic Diseases
por: Zhang, Weiyue, et al.
Publicado: (2021)

Pharmacotherapy for Alcohol Dependence: Anticraving Medications for Relapse Prevention
por: Jung, Young-Chul, et al.
Publicado: (2006)

Pharmacotherapy of pediatric metabolic syndrome
por: Kelishadi, Roya, et al.
Publicado: (2013)

Antiglaucoma pharmacotherapy
por: Tătaru, CP, et al.
Publicado: (2012)

Pharmacotherapy of Insomnia
por: Neubauer, David N, et al.
Publicado: (2018)

Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy
por: Lee, Seohyuk, et al.
Publicado: (2023)

Cardio-Metabolic Benefits of Plant-Based Diets
por: Kahleova, Hana, et al.
Publicado: (2017)

Environmental stressors and cardio-metabolic disease: part II–mechanistic insights
por: Münzel, Thomas, et al.
Publicado: (2017)

Functional properties of beetroot (Beta vulgaris) in management of cardio-metabolic diseases
por: Mirmiran, Parvin, et al.
Publicado: (2020)

An evidence-based toolbox for the design and implementation of selective-prevention primary-care initiatives targeting cardio-metabolic disease
por: Sonderlund, Anders Larrabee, et al.
Publicado: (2019)

Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma
por: Richard, Seidu A.
Publicado: (2020)

The Pivotal Immunoregulatory Functions of Microglia and Macrophages in Glioma Pathogenesis and Therapy
por: Richard, Seidu A.
Publicado: (2022)

Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids
por: Richard, Seidu A.
Publicado: (2021)

CARDIO-VASCULAR DISEASES
Publicado: (1957)

Cannot write session to /tmp/vufind_sessions/sess_pdgh1psffg50n6ln79dcaklnh6